Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model-Reference-Cited by-同舟云学术

Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model

Published:2020-05-21 Issue:6 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Beredaki Maria-Ioanna¹,Georgiou Panagiota-Christina¹,Siopi Maria¹,Kanioura Lamprini²,Andes David³,Arendrup Maiken Cavling⁴⁵⁶^ORCID,Mouton Johan W.²,Meletiadis Joseph¹²

Affiliation:

1. Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

2. Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands

3. Department of Medicine and Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA

4. Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark

5. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

6. Department of Clinical Microbiology, University of Copenhagen, Copenhagen, Denmark

Abstract

CLSI and EUCAST susceptibility breakpoints for voriconazole and Candida albicans differ by one dilution (≤0.125 and ≤0.06 mg/liter, respectively) whereas the epidemiological cutoff values for EUCAST (ECOFF) and CLSI (ECV) are the same (0.03 mg/liter). We therefore determined the pharmacokinetic/pharmacodynamic (PK/PD) breakpoints of voriconazole against C. albicans for both methodologies with an in vitro PK/PD model, which was validated using existing animal PK/PD data.

Funder

European Society of Clinical Microbiology and Infectious Diseases

Pfizer

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00170-20

Reference36 articles.

1. Excess Mortality, Hospital Stay, and Cost Due to Candidemia: A Case-Control Study Using Data From Population-Based Candidemia Surveillance

2. Candidemia is Costly--Plain and Simple